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Background: Interleukin (IL)-17A and IL-17E (also known as IL-25) have been implicated in fibrosis in various tissues.
However, the role of these cytokines in the development of intestinal strictures in Crohn’s disease (CD) has not
been explored. We investigated the levels of IL-17A and IL-17E and their receptors in CD strictured and non-strictured
gut, and the effects of IL-17A and IL-17E on CD myofibroblasts.
Results: IL-17A was significantly overexpressed in strictured compared with non-strictured CD tissues, whereas no
significant difference was found in the expression of IL-17E or IL-17A and IL-17E receptors (IL-17RC and IL-17RB,
respectively) in strictured and non-strictured CD areas. Strictured CD explants released significantly higher amounts of
IL-17A than non-strictured explants, whereas no difference was found as for IL-17E, IL-6, or tumor necrosis factor-α
production. IL-17A, but not IL-17E, significantly inhibited myofibroblast migration, and also significantly upregulated
matrix metalloproteinase (MMP)-3, MMP-12, tissue inhibitor of metalloproteinase-1 and collagen production by
myofibroblasts from strictured CD tissues.
Conclusions: Our results suggest that IL-17A, but not IL-17E, is pro-fibrotic in CD. Further studies are needed to clarify
whether the therapeutic blockade of IL-17A through the anti-IL-17A monoclonal antibody secukinumab is able to
counteract the fibrogenic process in CD.
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Fibrosis is the common end-stage of chronic inflammatory
diseases in many tissues. There is excessive accumulation
of extracellular matrix (ECM) components, including col-
lagen and fibronectin, in the damaged tissue, leading to
scarring and organ malfunction [1]. ECM-producing myofi-
broblasts are the key players of fibrotic tissue remodeling,
and consequently, much of the fibrosis research has fo-
cused on elucidating the molecular and immunological
mechanisms underlying myofibroblast activation, prolifer-
ation, and migration [2].
A number of cytokines can modulate myofibroblast
function, including those belonging to the interleukin* Correspondence: t.t.macdonald@qmul.ac.uk
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reproduction in any medium, provided the or(IL)-17 family [3,4]. In particular, IL-17A stimulates pro-
liferation and migration of cardiac fibroblasts [5], promotes
hepatic stellate cell activation into fibrogenic myofibroblasts
[6], induces collagen production by skin fibroblasts [7], and
promotes epithelial-mesenchymal transition of lung epithe-
lial cells [8]. IL-17E, also known as IL-25, upregulates pro-
inflammatory cytokine expression and collagen production
by lung fibroblasts [9,10].
We recently showed that IL-17A is increased in the in-
flamed areas of patients with inflammatory bowel disease
(IBD) [11]. By contrast, expression of IL-17E, which exerts
an anti-inflammatory action by inhibiting T helper (Th)1
and Th17 responses, is markedly reduced in the inflamed
mucosa of patients with IBD [12]. However, there is much
less clarity about the influence that these cytokines exert
on intestinal fibrosis, which is a frequent complication in
Crohn’s disease (CD) [13].al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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[14,15]. Myofibroblasts isolated from strictured gut tissue
of patients with CD overexpress collagen and transforming
growth factor (TGF)-β1, produce excessive amounts of tis-
sue inhibitor of metalloproteinases (TIMP)-1, and display
reduced migratory ability compared with myofibroblasts
isolated from non-strictured intestinal areas in CD [16]. Al-
though intestinal myofibroblasts are the target of a number
of pro-inflammatory cytokines, including IL-1β and tumor
necrosis factor (TNF)-α [17], no information is available
on expression of the IL-17A and IL-17E receptors (IL-
17RC and IL-17RB respectively), or on the effect of
IL-17A and IL-17E on the release of pro-fibrogenic me-
diators by these cells.
Thus, in this study, we assessed expression of IL-17A
and IL-17E in CD strictured and non-strictured gut, and
investigated IL-17A and IL-17E production by CD stric-
tured tissue explants cultured ex vivo. In addition, we
assessed IL-17A and IL-17E receptor expression in CD
strictured and non-strictured tissue and on myofibroblasts
from the same areas, and performed in vitro experiments
to determine the effects of IL-17A and IL-17E on CD
myofibroblasts.
Results
In vivo IL-17A and IL-17E tissue expression
We analyzed IL-17A and IL-17E levels by immunoblot-
ting in tissue samples collected from uninflamed areas
of strictured and non-strictured gut of 12 patients with
fibrostenosing CD and from normal gut of 11 control
subjects. IL-17A expression was significantly (P<0.005)
upregulated in strictured CD areas compared with non-
strictured CD areas and control gut (Figure 1A). No
significant difference in IL-17A expression was found
between non-strictured CD areas and control gut. IL-17E
levels did not differ significantly between strictured and
non-strictured CD areas and control gut.
In parallel, we analyzed IL-17A and IL-17E expression
by ELISA in the same samples. IL-17A was significantly
upregulated in strictured CD (mean 98.5 ± 13.7 pg/μg total
protein) compared with non-strictured CD (mean 42.3 ±
11.0 pg/μg total protein, P<0.005) and control (mean 46.5 ±
8.3 pg/μg total protein, P<0.005) areas (Figure 1B). There
was no significant difference in IL-17A expression be-
tween non-strictured CD areas and control gut. IL-17E
did not significantly differ between strictured CD (mean
222.5 ± 32.4 pg/μg total protein), non-strictured CD
(mean 178.1 ± 30.3 pg/μg total protein), and control areas
(mean 188.2 ± 35.3 pg/μg total protein).
In vivo IL-17RC and IL-17RB tissue expression
We then analyzed IL-17RC (receptor of IL-17A) and
IL-17RB (receptor of IL-17E) expression by immunoblot-
ting in the same tissue samples. IL-17RC expression wasnot significantly different between CD strictured, CD non-
strictured, and control gut (Figure 2A). Similarly, IL-17RB
expression did not differ between CD strictured, CD non-
strictured and control gut (Figure 2B).
Ex vivo tissue production of IL-17A, IL-17E, IL-6, TNF-α,
collagen and TGF-β1
We cultured ex vivo for 24 hours tissue explants (1 mm3
in size) from uninflamed areas of strictured and non-
strictured gut of six patients with fibrostenosing CD and
from normal gut of seven control subjects, and measured
IL-17A, IL-17E, IL-6, TNF-α, and collagen concentration
in the culture supernatant and TGF-β1 transcripts in the
cultured tissue (Figure 3). IL-17A was significantly higher
in the organ culture supernatants of strictured CD (mean
110.0 ± 23.8 pg/ml) than in those of non-strictured CD
(mean 55.9 ± 8.8 pg/ml, P<0.05) or normal gut (mean
51.1 ± 8.9 pg/ml, P<0.02). Concentrations of IL-17E, IL-6,
and TNF-α did not differ significantly between the su-
pernatants of strictured CD (mean 653.3 ± 283.5 pg/ml,
26,553 ± 6647 pg/ml, and 43.4 ± 7.6 pg/ml, respectively),
non-strictured CD (mean 1,028.0 ± 202.5 pg/ml, 31,740 ±
3944 pg/ml, and 40.8 ± 7.7 pg/ml, respectively), and normal
gut (mean 1068.0 ± 282.8 pg/ml, 36,784 ± 2516 pg/ml, and
30.0 ± 7.9 pg/ml, respectively). Collagen concentration was
significantly higher in the supernatants of strictured CD
(mean 979.0 ± 108.6 μg/ml, respectively) than in those of
non-strictured CD (mean 604.6 ± 97.5 μg/ml, P<0.05) and
normal gut areas (mean 523.6 ± 77.9 μg/ml, P=0.005).
TGF-β1 transcripts were significantly higher in the cul-
tured tissue explants from strictured CD than in those from
non-strictured CD (P=0.0005) and normal gut (P=0.001).
IL-17RC and IL-17RB expression on myofibroblasts
We then analyzed IL-17RC and IL-17RB expression by
immunoblotting in lysates of myofibroblasts isolated
from uninflamed areas of strictured and non-strictured
gut of six patients with fibrostenosing CD, and from nor-
mal gut of seven control subjects. Myofibroblasts isolated
from strictured CD areas, non-strictured CD areas, and
control gut expressed both IL-17RC (Figure 4A) and IL-
17RB (Figure 4B). However, no significant difference in
IL-17RC and IL-17RB expression was found between
strictured, non-strictured CD, and control myofibroblasts.
In vitro effect of IL-17A and IL-17E on matrix
metalloproteinase (MMP)-3, MMP-12, and TIMP-1
production by myofibroblasts
Matrix metalloproteinase (MMP)-3, MMP-12, and TIMP-
1 production was evaluated by immunoblotting in culture
supernatants of myofibroblasts isolated from uninflamed
areas of strictured or non-strictured gut of six patients
with fibrostenosing CD, and from normal gut of six con-
trol subjects, and subsequently stimulated in vitro with
Figure 1 In vivo expression of interleukin (IL)-17A and IL-17E. IL-17A and IL-17E were detected by both (A) immunoblotting and (B) ELISA in
uninflamed areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl) gut of 12 patients with fibrostenosing Crohn’s disease (CD) and
from normal gut of 11 healthy control (HC) subjects. (A) Each example shown in the upper panel is representative of experiments performed in
12 patients with CD and 11 HC subjects. Blots were stripped and analyzed for β-actin as an internal loading control. In the lower panel,
densitometry of IL-17A and IL-17E expression normalized for β-actin is shown. Results are mean ± SEM. au, Arbitrary units. (B) Results, expressed
as pg/100 μg of total protein, are mean ± SEM. *P<0.005 versus Non-strict uninfl and HC tissue samples.
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rhIL-17A and rhIL-17E induced a significant (P<0.05)
increase in both MMP-3 and MMP-12 production by
myofibroblasts from strictured and non-strictured areas
of patients with CD and from normal gut of control
subjects (Figure 5A,B). rhTNF-α induced a significant
(P<0.05) increase in both MMP-3 and MMP-12 produc-
tion compared with control (myofibroblasts from the
same group of patients cultured with medium alone).
No significant difference in MMP-3 or MMP-12production was found between rhTNF-α, rhIL-17A, and
rhIL-17E stimulation in the three conditions studied.
Myofibroblasts from CD strictured areas showed a sig-
nificantly (P<0.05) lower spontaneous release of MMP-12
than myofibroblasts from CD non-strictured areas or
control gut. Myofibroblast stimulation with rhIL-17A
induced a significant (P<0.05) increase in TIMP-1 produc-
tion compared with unstimulated cells from the same
group of patients (Figure 5C). rhIL-17E did not induce
any significant change in TIMP-1 production compared
Figure 2 In vivo expression of interleukin (IL)-17A and IL-17E receptors. (A) IL-17RC (receptor of IL-17A), and (B) IL-17RB (receptor of IL-17E)
were detected by immunoblotting in uninflamed areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl) gut of 12 patients with
fibrostenosing Crohn’s disease (CD) and from normal gut of 11 healthy control (HC)subjects. Each example shown in the left panels is
representative of experiments performed in all patients with CD and all HC subjects. Blots were stripped and analyzed for β-actin as an internal
loading control. In the right panels, densitometry of IL-17RC and IL-17RB expression normalized for β-actin is shown. Results are mean ± SEM. au,
Arbitrary units.
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tured with medium alone. rhTNF-α induced a significant
(P<0.05) increase in TIMP-1 production compared with
myofibroblasts from the same group of patients cul-
tured with medium alone. No significant difference in
TIMP-1 production was found between rhTNF-α and
rhIL-17A stimulation in all the three conditions
studied.
In vitro effect of IL-17A and IL-17E on myofibroblast
collagen production
We cultured myofibroblasts isolated from uninflamed areas
of strictured and non-strictured gut of six patients with
fibrostenosing CD, and from normal gut of six control sub-
jects, in the presence or absence of rhTNF-α, rhIL-17A, or
rhIL-17E, and measured collagen in the culture superna-
tants (Figure 6). Myofibroblast stimulation with rhIL-17A
induced a significant (P<0.05) increase in mean collagen
production (strictured CD myofibroblasts: 412 ± 57 μg/ml;
non-strictured CD myofibroblasts: 154 ± 17 μg/ml;control myofibroblasts: 114 ± 12 μg/ml) compared with
cells from the same group of patients cultured with
medium alone (strictured CD myofibroblasts: 155 ± 23
μg/ml; non-strictured CD myofibroblasts: 76 ± 15 μg/ml;
control myofibroblasts: 67 ± 7 μg/ml). rhIL-17E did not
induce any significant change in mean collagen produc-
tion by strictured CD myofibroblasts (181 ± 37 μg/ml),
non-strictured CD myofibroblasts (83 ± 7 μg/ml) or con-
trol myofibroblasts (61 ± 10 μg/ml) compared with un-
stimulated cells from the same group of patients. rhTNF-α
induced a significant (P<0.05) increase in mean collagen
production by strictured CD myofibroblasts (399 ± 62 μg/
ml), non-strictured CD myofibroblasts (175 ± 22 μg/ml)
and control myofibroblasts (124 ± 18 μg/ml) compared
with unstimulated cells from the same group of patients.
No significant difference in collagen production was found
between cells cultured with rhTNF-α and rhIL-17A. Stric-
tured CD myofibroblasts produced significantly (P<0.05)
higher amounts of collagen than did non-strictured CD
and control myofibroblasts cultured under the same
Figure 3 Levels of cytokines and pro-fibrogenic mediators in tissue explant organ culture supernatants. Levels of interleukin (IL)-17A, IL-17E,
IL-6, and tumor necrosis factor (TNF)-α, expressed as pg/ml, and collagen, expressed as μg/ml, in the supernatants of tissue explants from uninflamed
areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl) gut of six patients with fibrostenosing Crohn’s disease (CD) and from normal gut
of seven control subjects (HC), cultured for 24 hours in the absence of stimuli, and levels of transforming growth factor (TGF)-β1, expressed as relative
units compared with the median expression in control subjects (which was assigned the value 1), in the same cultured tissue explants. Values are
mean ± SEM. r.u., Relative units.
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tion was found between non-strictured CD and control
myofibroblasts cultured under the same conditions.
In vitro effect of IL-17A and IL-17E on myofibroblast migration
To evaluate the role of IL-17A and IL-17E on myofibroblast
migration, a wound-healing scratch assay was performed
using subconfluent monolayers of myofibroblasts isolatedfrom uninflamed areas of strictured and non-strictured gut
of six patients with fibrostenosing CD, and from normal
gut of seven control subjects. Cell migration was mea-
sured as the percentage of wound repair and results
were expressed as mean percentage of wound repair
(see Methods section). rhIL-17A significantly (P<0.05) re-
duced migration of strictured CD, non-strictured CD and
control myofibroblasts at 8 hours (3.2 ± 1.1%, 4.6 ±
Figure 4 Expression of interleukin (IL)-17A and IL-17E receptors on intestinal myofibroblasts. (A) IL-17RC and (B) IL-17RB were detected
by immunoblotting on lysates of myofibroblasts isolated from uninflamed areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl)
gut of six patients with fibrostenosing Crohn’s disease (CD) and from normal gut of seven healthy control (HC) subjects. Each example shown in
the left panels is representative of experiments performed in all patients with CD and all HC subjects. Blots were stripped and analyzed for β-actin
as an internal loading control. In the right panels, densitometry of IL-17RC and IL-17RB expression normalized for β-actin is shown. Results are
mean ± SEM. au, Arbitrary units.
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8.4 ± 1.8%, and 10.6 ± 1.9%, respectively) and 24 hours
(8.8 ± 1.9%, 23.2 ± 2.3%, and 29.7 ± 2.0%, respectively)
compared with myofibroblasts from the same three
groups cultured with medium alone and evaluated at the
same time points (8 hours 9.8 ± 1.3%, 13.7 ± 1.8%, and
14.6 ± 1.7%, respectively; 16 hours: 15.6 ± 1.6%, 25.3 ±
2.3%, and 20.3 ± 1.1%, respectively; and 24 hours: 30.6 ±
2.3%, 49.1 ± 1.9%,and 48.4 ± 1.8%, respectively) (Figure 7).
Compared with medium alone, rhIL-17E did not induce
any significant change in strictured CD, non-strictured
CD, and control myofibroblast migration (8 hours: 11.2 ±
1.2%, 15.4 ± 1.4%, 12.9 ± 1.5%, respectively; 16 hours:
16.2 ± 1.4%, 28.2 ± 1.7%, 25.1 ± 1.1%, respectively; and 24
hours: 26.3 ± 1.9%, 41.3 ± 2.2%, 43.4 ± 2.2%, respectively).
Discussion
In the present study, we found that IL-17A was over-
expressed in CD strictures compared with non-stricturedCD areas and control gut. We also found that myofibroblasts
from CD strictures, which express the IL-17A receptor
(IL-17RC), responded to IL-17A by producing more colla-
gen and TIMP-1, and had reduced migratory ability. By
contrast, IL-17E was not upregulated in CD strictures,
and it did not influence collagen and TIMP-1 production
or migration of myofibroblasts from CD strictures.
IL-17A, which is produced mainly by Th1 and Th1/
Th17 cells [18,19], mediates autoimmunity and immune
defense against pathogens [20], and is increased in the in-
testinal mucosa of patients affected by chronic inflamma-
tory bowel disorders, such as celiac disease [21], CD, and
ulcerative colitis [22,23]. Moreover, experimental studies
have shown an important role for IL-17A in tissue remod-
eling and fibrosis in a number of different tissues. In
particular, IL-1β-induced and bleomycin-induced lung
fibrosis seems to depend on the action of IL-17A, and in
addition, IL-17A−/− mice are less susceptible to experi-
mental skin fibrosis [7,24]. As opposed to acute
Figure 5 (See legend on next page.)
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Figure 5 Effect of interleukin (IL)-17A and IL-17E on the production of matrix metalloproteinase (MMP)-3, MMP-12, and tissue inhibitor
of metalloproteinase (TIMP)-1 by intestinal myofibroblasts. (A) MMP-3, (B) MMP-12, and (C) (TIMP-1 in culture supernatants of
myofibroblasts isolated from uninflamed areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl) gut of six patients with
fibrostenosing Crohn’s disease (CD) and from normal gut of six healthy control (HC) subjects, cultured for 24 hours with medium alone or
recombinant human (rh) tumor necrosis factor (TNF)-α, or rhIL-17A, or rhIL-17E. Blots are representative of experiments performed in all patients
with CD and HC subjects. Lower panels show densitometry of western blots. Values are mean ± SEM. *P<0.05 versus myofibroblasts from the
same study group cultured with medium alone. §P<0.05 versus Non-strict uninfl CD and HC myofibroblasts cultured under the same conditions.
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Th1 immune response, chronic trinitrobenzenesulfonic
acid (TNBS)-induced murine colitis, which is accom-
panied by intestinal fibrosis, is driven predominantly by
IL-17A-producing Th17 cells [25]. The observation that
targeting IL-23 (a key cytokine in Th17 cell development)
with a p40 peptide-based vaccine ameliorates chronic
TNBS-induced colitis,and reduces IL-17A, TGF-β1 levels,
and collagen deposition in the bowel wall [25], highlights
the importance of IL-17A in intestinal experimental fibrosis.
In the current study, we found, using immunoblotting
and ELISA, that IL-17A was overexpressed in vivo in
strictured CD gut compared with non-strictured CD and
control gut. We decided to collect samples from unin-
flamed areas of patients with fibrostenosing CD so that
any confounding effect of inflammation on IL-17A was
minimized. Similar to the in vivo data, ex vivo tissue
explants from CD strictures produced more IL-17A than
explants from non-strictured CD areas and control gut. In
keeping with our previous results [16], collagen content
and TGF-β1 transcripts in tissue explants from unin-
flamed CD strictures were also increased compared with
uninflamed non-strictured CD areas and control gut.
The recent observation that IL-17A expression is higherFigure 6 Effect of interleukin (IL)-17A and IL-17E on the production o
expressed as μg/ml, in the supernatants of myofibroblasts isolated from un
uninfl) gut of six patients with fibrostenosing Crohn’s disease (CD) and from
with medium alone or recombinant human (rh)tumor necrosis factor (TNF)
myofibroblasts from the same study group cultured with medium alone. §P
under the same conditions.in long-standing CD mucosa compared with early mucosal
lesions [26] further strengthens our findings, because intes-
tinal fibrosis is a late-stage process in CD.
On the basis of our findings showing that CD myo-
fibroblasts expressed the IL-17A receptor IL-17RC we
decided to stimulate these cells with IL-17A in in vitro
experiments. In keeping with the study of Bamba et al.
[27], we found that IL-17A increased MMP-3 and MMP-12
production by myofibroblasts from CD strictured and non-
strictured areas. However, in parallel, IL-17A upregulated
TIMP-1 and collagen release, and reduced the migration
ability of CD myofibroblasts. In a murine model of intes-
tinal fibrosis, TIMP-1, which is upregulated, effectively
inhibited ECM degradation by MMPs [28], and TIMP-1
was found to be increased in collagenous colitis and in
CD strictures [16,29]. Taken together, our data support a
pro-fibrogenic role for IL-17A in CD intestinal fibrosis.
In parallel to studying the role of IL-17A, we also inves-
tigated the influence of IL-17E in the fibrogenic process in
CD. IL-17E exerts two distinct immunological functions:
on the one hand, it promotes Th2 response in allergic dis-
eases including asthma [30], while on the other hand, it
dampens the inflammatory process in immune-mediated
disorders including IBD [31]. A pro-fibrogenic role forf collagen by intestinal myofibroblasts. Levels of collagen,
inflamed areas of strictured (Strict uninfl) and non-strictured (Non-strict
normal gut of six healthy control (HC) subjects, cultured for 24 hours
-α, or rhIL-17A, or rhIL-17E. Values are mean ± SEM. *P<0.05 versus
<0.05 versus Non-strict uninfl CD and HC myofibroblasts cultured
Figure 7 Wound-healing scratch assay. Effect of recombinant human (rh)IL-17A and rhIL-17E on the migration, assessed by an in vitro wound-healing
scratch assay, of myofibroblasts isolated from uninflamed areas of strictured (Strict uninfl) and non-strictured (Non-strict uninfl) gut of six patients with
fibrostenosing Crohn’s disease (CD) and from normal gut of seven healthy control (HC) subjects. Myofibroblasts were cultured with rhIL-17A or
rhIL-17E or medium alone. Results, expressed as percentage of wound repair, are mean ± SEM. *P<0.05 versus myofibroblasts cultured with
medium only at 8, 16, and 24 hours.
Table 1 Clinical features of patients with fibrostenosing
Crohn’s disease (n=29)
Characteristics and parameters n Median (range)
Age, years 35.8 (23 to 61)
First attack 6
Intestinal location
Small bowel and colon 15
Small bowel only 9
Colon only 5
Duration of disease, months 81.2 (7 to 196)
Number of recurrences 4 (0 to 9)
CDAI 223 (155 to 426)
Treatment
Mesalazine 13
Topical steroids 3
Antibiotics 9
Azathioprine/6-MP/methotrexate 14
Abbreviations: CDAI Crohn’s Disease Activity Index, 6-MP 6-mercaptopurine.
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shown. In particular, IL-17E mediates pulmonary colla-
gen deposition in mice exposed to house dust mite [10],
and intestinal TNBS-induced fibrosis was found to be
associated in the early phase by a marked increase in
IL-17E [32]. When we investigated IL-17E in vivo, we
found no difference in the expression of IL-17E in un-
inflamed CD strictures, uninflamed non-strictured CD
areas, and control gut. Likewise, ex vivo tissue explants
from the same three groups of patients produced compar-
able amounts of IL-17E. The IL-17E receptor IL-17RB was
expressed at a similar level in strictured, non-strictured
CD, and control gut. IL-17RB was found to be expressed
by CD myofibroblasts, and stimulation with IL-17E in-
creased MMP-3 and MMP-12 production by myofibroblasts
from CD strictured and non-strictured areas and from
control subjects. However, we did not observe any influ-
ence of IL-17E on collagen or TIMP-1 production by CD
myofibroblasts or on their migration ability.
Conclusions
In conclusion, our findings provide evidence that IL-17A,
but not IL-17E, may have a pro-fibrogenic role in CD. Clin-
ical studies are needed to ascertain whether therapeutic
blockade of IL-17A through the monoclonal anti-
IL-17A antibody secukinumab [33] might offer a chance
to counteract the fibrogenic process in patients with CD.
However, we must emphasize that the recent findings
that anti-IL-17A exacerbates CD [33] will mean that
patient selection for such treatment will be crucial.
Methods
Ethics approval
This study was approved by the local Ethics Committee
(NRES Committee London - City & East). Each patient
who took part in the study gave informed consent to par-
ticipate in the study and to publish the results derivingfrom this research. All the experiments reported in this
study are in compliance with the Helsinki Declaration.
Patients and tissues
Surgical specimens were taken from uninflamed areas
of strictured and non-strictured ileum or colon of 29
patients with fibrostenosing CD (Table 1). Because the
excessive collagen deposition occurs in the sub-mucosa
and outer muscle layers, we discarded the mucosa upon
dissection, and used the muscle-enriched fraction. Diag-
nosis of CD was ascertained by standard clinical criteria
[34], and strictured areas were identified by enteroclysis
[35]. None of the patients with CD had been treated previ-
ously with ciclosporin, tacrolimus, methotrexate, or anti-
TNF-α antibodies. Intestinal samples were also collected
from macroscopically and microscopically unaffected (at
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27 patients undergoing intestinal resection for colon can-
cer (mean age 57 years, range 45–71 years). The intestinal
tissue was homogenized and used in immunoblotting ex-
periments, or processed to isolate myofibroblasts, or cul-
tured ex vivo.
Organ culture
Intestinal tissue explants (1 mm3 in size) were placed in
12-well tissue culture plates (BD Biosciences, Oxford,
UK; one explant per well) and cultured at 37°C and 5%
CO2 in 800 μl serum-free HL-1 medium (Cambrex Bio
Science, Wokingham, UK) supplemented with 100 U/ml
penicillin and 100 μg/ml streptomycin, as previously de-
scribed [36]. After 24 hours ex vivo culture, supernatants
were collected and stored at −70°C until used for cytokine
measurement by ELISA, and intestinal explants were ho-
mogenized for subsequent evaluation of TGF-β1 expres-
sion by quantitative reverse transcription (qRT)-PCR.
Myofibroblast isolation and culture
The mucosa was dissected away from full thickness
samples of bowel and discarded. The remaining tissue
was cut into 1 mm-sized cubes and cultured at 37°C in a
humidified CO2 incubator in Dulbecco’s modified Eagle’s
medium (DMEM; Sigma-Aldrich, Poole, UK) supplemented
with 20% fetal bovine serum (FBS), 1% non-essential amino
acids (Invitrogen Ltd., Paisley, UK), 100 U/ml penicillin,
100 μg/ml streptomycin, 50 μg/ml gentamycin, and 1 μg/ml
amphotericin (Sigma-Aldrich). Myofibroblasts migrated
out of the tissue after a few days. Established colonies of
myofibroblasts were seeded into 25-cm2 culture flasks
and cultured in DMEM supplemented with 20% FBS
and antibiotics. At confluence, the cells were passaged
using trypsin-EDTA in a 1:2 to 1:3 split ratio. Cells were
grown to at least passage 4 before there were enough to
use in stimulation experiments, and were characterized
by immunocytochemical staining, as previously described
[37]. Subconfluent monolayers of myofibroblasts seeded
in 12-well plates at 3×105 cells per well were starved in
serum-free medium for 24 hours at 37°C and 5%CO2
before culture for 24 hours at 37°C and 5%CO2 with
serum-free DMEM containing antibiotics in the absence
or presence of 10 ng/ml of rhIL-17A, or rhIL-17E, or
rhTNF-α (all R&D Systems, Abingdon, Oxfordshire, UK).
Wound-healing scratch assay
Myofibroblast migration was assessed in accordance with
the modified method of Rodriguez et al. [16,38]. Briefly,
cells (2×105) were seeded into cell culture dishes (Nunc;
Nalge Nunc International, Rochester, NY, USA) with 2 mm
grids, size 35×10 mm, in 2 ml of DMEM supplemented
with 20% FBS and antibiotics. The cells were maintained at
37°C and 5% CO2 until confluent. Once confluent, eachdish of monolayer cells was given a mechanical wound by
scoring with a 200 μl pipette tip, parallel to the grid bars
along the central grid line. This permitted easy viewing of
the cells growing back together, and ensured that the 2 mm
grid could be used as a reference, so that the wound areas
could be measured and compared. Wound placement was
checked with an inverted microscope (CK2; Olympus UK
Ltd, London, UK). The medium was then removed, and the
cells were washed five times with HL-1 serum-free medium
(Cambrex Bio Science) supplemented with antibiotics, and
then replaced with 1.5 ml HL-1 medium with or without
10 ng/ml rhIL-17A or rhIL-17E (both R&D Systems). Pho-
tographs of the cells in each grid along the induced wound
were taken at 0, 2, 4, 8, 16 and 24 hours, using a digital
camera (Camedia; Olympus UK Ltd) with 34 to 40 zoom,
and 20× magnification, attached to a light microscope. The
computer program Image J was used to measure the
area of initial damage (images taken at time 0) and of
the remaining damage at subsequent time points. Each
grid image was observed separately, and two points per
grid at the same position at every time point were mea-
sured using imaging software at the same magnification.
The percentage of wound repair was then calculated.
ELISA
Concentrations of IL-17A and IL-17E in tissue sample
homogenates were measured using specific ELISA kits
(R&D Systems), in accordance with the manufacturer’s
instructions, and were normalized to the total protein
concentration, determined by a protein assay (Bio-Rad
Laboratories, Hemel Hempstead, UK). Concentrations
of IL-17A, IL-17E, IL-6, and TNF-α in organ-culture super-
natants were assessed using specific ELISA kits (R&D Sys-
tems), in accordance with the manufacturer’s instructions.
RNA extraction and analysis of mRNA expression
by qRT-PCR
RNA was extracted from cultured tissue explants.
cDNAs were synthesized (Improm-II RT system; Promega,
Southampton, Hampshire, UK) using random hexamers
and 1 μg of RNA in a final volume of 20 μl. RT reactions
were performed using the Improm-II reverse transcriptase
enzyme from the kit. An RT reaction without reverse tran-
scriptase enzyme was performed for each tissue type as a
negative control for qPCR. TGF-β1 primers and probe
sets were validated for use with the ΔΔCt method of quan-
tification. The probe was labeled with a 59-reporter dye
FAM (6-carboxy-fluorescein) and the 39-quencher dye
TAMRA (6-carboxy-N,N,N’,N9-tetramethyl-rhodamine). RT
reactions were diluted 1 in 10 in distilled H2O, and 5 μl
of template was added to 6.5 μl of 2× master mix
(Eurogentech, Seraing, Belgium) containing 1.2 μmol/l
forward and reverse primers and 0.248 μmol/l of probe
in a total volume of 12.5 μl. The PCR protocol was as
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followed by 40 cycles of denaturation at 95°C for 15
seconds, and annealing/extension at 60°C for 1 minute.
Thermocycling and real-time detection of PCR products
were performed on asequence detection system (iCycler
iQ; Bio-Rad Laboratories). Expression levels were normal-
ized against 18S, β-actin, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), and values were calculated using
the ΔΔCt method.
Collagen assay
Total soluble forms of collagen were measured in super-
natants of tissue explants and myofibroblasts (Sircol Col-
lagen Assay Kit; Biocolor Ltd, Belfast, UK), in accordance
with the manufacturers’ instructions. The collagen con-
tent in each sample was calculated as an average of
three readings.
Western blotting
Western blotting was performed using a modification of
a previously described method [36]. Tissue samples or
myofibroblasts were homogenized in ice-cold lysis buf-
fer, and the amount of protein was determined by a pro-
tein assay (Bio-Rad Laboratories). Equal amounts of
protein or 15 μl of cell- culture supernatants were loaded
into each lane and run in 10% sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) gels under
reducing conditions. After electrophoresis, protein was
transferred onto nitrocellulose membranes (Bio-Rad La-
boratories). Membranes were blocked with 5% non-fat
dry milk, followed by incubation overnight at 4°C with
the following antibodies: goat anti-human IL-17A (1 μg/ml),
goat anti-human IL-17E (0.1 μg/ml) (both R&D Systems),
mouse anti-human IL-17RB (1:500 dilution; LifeSpan Biosci-
ences, Seattle, WA), mouse anti-human IL-17RC (1:750
dilution), rabbit anti-human MMP-3 (1:200 dilution),
rabbit anti-human MMP-12 (1:1000 dilution) (all three
from Abcam Ltd, Cambridge, UK), or mouse anti-human
TIMP-1 (1 μg/ml; Oncogene Research, Nottingham, UK).
Appropriate antibodies conjugated to horseradish perox-
idase (Dako, High Wycombe, Buckinghamshire, UK) were
used as secondary antibodies, and the reaction was devel-
oped with enhanced chemiluminescence (ECL Plus Kit;
Amersham Biosciences, Little Chalfont, Buckinghamshire,
UK). Blots were then stripped and analyzed for β-actin, as
an internal loading control, using a rabbit anti-β-actin
antibody (1:5000 dilution; Abcam Ltd). Bands were quan-
tified by scanning densitometry (LKB Ultrascan XL Laser
Densitometer; Kodak, Hemel Hempstead, UK).
Statistical analysis
Data were analyzed by the GraphPad Prism statistical
PC program (GraphPad Software, San Diego, CA) usingthe paired t test and the Mann–Whitney U-test. P<0.05
was considered significant.
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